What's New

CE Education
The Future Impact of Novel Therapies on the Frontline Treatment of Hodgkin Lymphoma
Stephen M. Ansell, MD, PhD
CE Education
Navigating Treatment Pathways in Relapsed/Refractory Hodgkin Lymphoma
John Sweetenham, MD, FRCP, FACP
Clinical Case Snapshots
23-year-old female who presented with progressive dyspnea on exertion
Matthew Matasar, MD
CE Education
2017 EHA Annual Meeting Highlights
Peter Borchmann, MD; Paul Bröckelmann, MD; Andreas Engert, MD; Andrea Gallamini, MD; Hayder Saeed, MD; Anas Younes, MD
CE Education
Incorporating Immunotherapy in the Treatment of Hodgkin Lymphoma
Craig Moskowitz, MD
Clinical Pearls Podcasts
Listen or download these brief audio clips to use at the point of care in your practice!
FAQ Library
What is the role of brentuximab vedotin as first line salvage therapy prior to ASCT?
John Sweetenham, MD, FRCP, FACP

Managing HL would like to recognize and thank Merck & Co., Inc., Seattle Genetics, and Takeda Oncology for their educational support of ManagingHodgkinLymphoma.com

©2018 MediCom Worldwide, Inc. All rights reserved